MA33132B1 - Derives pyrazole utilises comme antagonistes du recepteur ccr4 - Google Patents

Derives pyrazole utilises comme antagonistes du recepteur ccr4

Info

Publication number
MA33132B1
MA33132B1 MA34179A MA34179A MA33132B1 MA 33132 B1 MA33132 B1 MA 33132B1 MA 34179 A MA34179 A MA 34179A MA 34179 A MA34179 A MA 34179A MA 33132 B1 MA33132 B1 MA 33132B1
Authority
MA
Morocco
Prior art keywords
receptor antagonists
pyrazole derivatives
ccr4 receptor
ccr4
compounds
Prior art date
Application number
MA34179A
Other languages
Arabic (ar)
English (en)
Inventor
Heather Hobbs
Simon Teanby Hodgson
Yannick Maurice Lacroix
Deborah Needham
Nigel James Parr
Panayiotis Alexandrou Procopiou
Timothy John Ritchie
Michael David Woodrow
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA33132B1 publication Critical patent/MA33132B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés indazole (I), des procédés pour leur préparation, des intermédiaires pouvant être utilisés dans ces procédés, des compositions pharmaceutiques contenant de tels composés et leur utilisation en thérapie liée aux antagonistes du récepteur CCR4.
MA34179A 2009-02-26 2010-02-24 Derives pyrazole utilises comme antagonistes du recepteur ccr4 MA33132B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15570209P 2009-02-26 2009-02-26
PCT/EP2010/052307 WO2010097395A1 (fr) 2009-02-26 2010-02-24 Dérivés pyrazole utilisés comme antagonistes du récepteur ccr4

Publications (1)

Publication Number Publication Date
MA33132B1 true MA33132B1 (fr) 2012-03-01

Family

ID=42110309

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34179A MA33132B1 (fr) 2009-02-26 2010-02-24 Derives pyrazole utilises comme antagonistes du recepteur ccr4

Country Status (31)

Country Link
US (3) US8304446B2 (fr)
EP (1) EP2401270B1 (fr)
JP (1) JP5520969B2 (fr)
KR (1) KR20110128896A (fr)
CN (1) CN102388039B (fr)
AR (1) AR075594A1 (fr)
AU (2) AU2010217629A1 (fr)
BR (1) BRPI1013396A2 (fr)
CA (1) CA2753337A1 (fr)
CL (1) CL2011002103A1 (fr)
CO (1) CO6420342A2 (fr)
DK (1) DK2401270T3 (fr)
DO (1) DOP2011000272A (fr)
EA (1) EA021740B1 (fr)
ES (1) ES2439773T3 (fr)
HK (1) HK1159621A1 (fr)
HR (1) HRP20131174T1 (fr)
IL (1) IL214655A0 (fr)
MA (1) MA33132B1 (fr)
MX (1) MX2011008972A (fr)
NZ (1) NZ594641A (fr)
PE (1) PE20120307A1 (fr)
PL (1) PL2401270T3 (fr)
PT (1) PT2401270E (fr)
RS (1) RS53133B (fr)
SG (1) SG173768A1 (fr)
SI (1) SI2401270T1 (fr)
SM (1) SMT201400001B (fr)
TW (1) TW201041879A (fr)
UY (1) UY32464A (fr)
WO (1) WO2010097395A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2559693B1 (fr) 2007-08-31 2014-11-26 Eisai R&D Management Co., Ltd. Composé polycyclique
AU2010218667A1 (en) 2009-02-26 2011-07-21 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
WO2010098487A1 (fr) 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Composés hétérocycliques condensés contenant de l'azote et leur utilisation en tant qu'inhibiteurs de production de la bêta-amyloïde
US8729260B2 (en) * 2010-05-19 2014-05-20 Savior Lifetec Corporation Process for the preparation of carbapenem using cabapenem intermediates and recovery of cabapenem
WO2012025473A1 (fr) * 2010-08-24 2012-03-01 Glaxo Group Limited Antagonistes du récepteur 4 des chimiokines cc
CA3195815A1 (en) * 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
JP6985388B2 (ja) 2016-07-29 2021-12-22 ラプト・セラピューティクス・インコーポレイテッド ケモカイン受容体調節剤及びそれの使用
US10246462B2 (en) 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190192A1 (ar) * 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين
WO2018187509A1 (fr) 2017-04-04 2018-10-11 Flx Bio, Inc. Composés hétérocycliques utilisés en tant que modulateurs du récepteur de chimiokine
EP3609883B1 (fr) * 2017-04-11 2022-06-29 Sunshine Lake Pharma Co., Ltd. Composés indazole substitués par fluor et leurs utilisations
AU2018360766A1 (en) 2017-11-06 2020-05-21 Rapt Therapeutics, Inc. Anticancer agents
CN110028501B (zh) * 2018-01-12 2022-02-22 迈德欣国际有限公司 化合物及其制备方法和用途
JP7355758B2 (ja) 2018-01-26 2023-10-03 ラプト・セラピューティクス・インコーポレイテッド ケモカイン受容体調節剤及びその使用
CN113893220A (zh) * 2020-07-07 2022-01-07 迈德欣国际有限公司 鼻粘膜给药剂型和其应用
US20230322741A1 (en) 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0316606A (pt) 2002-12-12 2005-10-11 Aventis Pharma Sa Derivados de aminoindazóis e sua utilização como inibidores de quinases
FR2848554A1 (fr) * 2002-12-12 2004-06-18 Aventis Pharma Sa Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
WO2008089307A2 (fr) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Méthodes et compositions utilisés dans le traitement de la douleur, de l'inflammation et du cancer

Also Published As

Publication number Publication date
HK1159621A1 (en) 2012-08-03
EA201190142A1 (ru) 2012-05-30
US20120015932A1 (en) 2012-01-19
US8304446B2 (en) 2012-11-06
EA021740B1 (ru) 2015-08-31
MX2011008972A (es) 2011-12-14
US20100216860A1 (en) 2010-08-26
CL2011002103A1 (es) 2012-02-24
PE20120307A1 (es) 2012-04-04
AU2010217629A1 (en) 2011-09-15
EP2401270B1 (fr) 2013-10-16
CN102388039A (zh) 2012-03-21
UY32464A (es) 2010-09-30
US20130030031A1 (en) 2013-01-31
ES2439773T3 (es) 2014-01-24
US8357716B2 (en) 2013-01-22
CO6420342A2 (es) 2012-04-16
PT2401270E (pt) 2014-01-20
NZ594641A (en) 2013-03-28
US8507543B2 (en) 2013-08-13
TW201041879A (en) 2010-12-01
DK2401270T3 (da) 2014-01-13
RS53133B (en) 2014-06-30
PL2401270T3 (pl) 2014-03-31
HRP20131174T1 (hr) 2014-01-17
JP2012518673A (ja) 2012-08-16
AU2016203684A1 (en) 2016-06-23
BRPI1013396A2 (pt) 2016-03-29
SMT201400001B (it) 2014-03-07
SI2401270T1 (sl) 2014-01-31
AR075594A1 (es) 2011-04-20
IL214655A0 (en) 2011-09-27
KR20110128896A (ko) 2011-11-30
JP5520969B2 (ja) 2014-06-11
CN102388039B (zh) 2015-07-15
WO2010097395A1 (fr) 2010-09-02
EP2401270A1 (fr) 2012-01-04
SG173768A1 (en) 2011-09-29
DOP2011000272A (es) 2011-12-31
CA2753337A1 (fr) 2010-09-02

Similar Documents

Publication Publication Date Title
MA33132B1 (fr) Derives pyrazole utilises comme antagonistes du recepteur ccr4
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
UA99132C2 (ru) Производные дикарбоновых кислот как агонисты рецепторов s1p1
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
MA31470B1 (fr) Dérivés de pipéridine utiles comme antagonistes vis-à-vis des récepteurs de l'orexine
WO2009106980A3 (fr) Dérivés d'indazole
WO2008021849A3 (fr) Nouveaux composés comme antagonistes ou agonistes inverses à des récepteurs d'opioïdes
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
IL193479A0 (en) Modulators of muscarinic receptors
MX2010009462A (es) Derivados de indazol.
GEP20135806B (en) Lactams as beta secretase inhibitors
MA34094B1 (fr) Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA39163B1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
EA201170256A1 (ru) Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d2 рецепторов дофамина
MA32479B1 (fr) Compoés nouveaux actifs comme antagonistes des recepteurs muscariniques
MA31863B1 (fr) Dérivés de pyrazole comme inhibiteurs de 5-lo
UA83868C2 (ru) Производные бензимидазолона и хиназолинона в качестве агонистов человеческих рецепторов orl1
MA32062B1 (fr) Sels de triazolium comme inhibiteurs de par1, leur production et leur utilisation comme médicaments
ATE461172T1 (de) Azetidinderivate als antagonisten des muskarinrezeptors
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MY152685A (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments